-
Nov 26, 2024 | 
onclive.com | Mary Beasley
The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic CancerMary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
-
Nov 26, 2024 | 
onclive.com | Mary Beasley
The Role of RNA in Detecting NRG1 and Other Fusions in Solid TumorsMary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
-
Nov 26, 2024 | 
onclive.com | Mary Beasley
Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PNDr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma
-
Jul 31, 2024 | 
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
-
Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
-
Jul 31, 2024 | 
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
-
Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Fred R. Hirsch, MD, PhD, leads a discussion with his Mount Sinai colleagues about important biomarkers found in non-small cell lung cancer, including those that provide predictive and prognostic information.
-
Jul 31, 2024 | 
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
-
Jul 31, 2024 | cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
-
Jul 31, 2024 | 
cancernetwork.com | Fred R. Hirsch |Mary Beasley |Nicole Hall |Philip C. Mack |Daniel G Nicastri |Nicholas Rohs | +1 more
Non-small cell lung cancer experts share biomarker testing protocols and best practices for optimal outcomes, with a focus on overcoming challenges and nuances of testing.
